For the Health of Billions
YIKON

Yikon Genomics was established in 2012 It is a high-tech enterprise dedicated to the development and application of single-cell whole-genome amplification and sequencing technologies, and provides precision medical detection technology for the fields of eugenics and early diagnosis of tumors

Currently, Yikon Genomics includes Shanghai Xukang Medical Technology Co., Ltd., Shanghai Yikon Medical Laboratory Co., Ltd., Suzhou Yikon Medical Laboratory Co., Ltd. and Xukang Medical Technology (Suzhou) Co., Ltd and two offices located in Guangzhou and Wuhan.

As a Knowledge-Intensive Enterprise in the precision medicine industry, Yikon Genomics has established a high-level technical and management team, of which 78% have a bachelor's degree or above, 34% have a master's degree or above, and 8% have a doctoral degree. The talents from Harvard University, Vanderbilt University, University of California, Berkeley, and University of Guelph in Canada, returned to China and are responsible for technology. Moreover, academicians of the American Academy of Sciences and domestic science leaders served as consultants to the scientific committee; at the same time, Yikon Genomics strictly controlled the quality of products and testing services, which have passed ISO9001:2015 and ISO13485: 2016 International Quality Certification. Yikon Medical Laboratory obtained the "The Practice License of Medical Institution" approved by the Shanghai Municipal Health Commission, which permits to provide domestic and foreign medical institutions, scientific research institutes, groups and individuals with Nearly a hundred testing services in fields of reproductive genetics, maternal and child health, tumor screening and life science research. In June 2017, Yikon Genomics PGS Kit passed the special approval of CFDA for innovative medical devices.

At present, Yikon Genomics has provided kits and medical testing services to more than 100 large domestic medical institutions, including the Third Hospital of Peking University, the General Hospital of the People's Liberation Army (301 Hospital), and the First Affiliated Hospital of Zhengzhou University, as well as world-class scientific research institutes. The preimplantation embryo genetic screening/diagnosis (PGS/PGD) service of Yikon Genomics can detect more than one hundred chromosomal genetic diseases and single-gene genetic diseases, and the cumulative number of services has exceeded 10,000. The group has established branches in Beijing, Shanghai, Jiangsu and California in the United States. Its business covers 32 provinces and municipalities directly under the Central Government. It has successfully expanded to more than 20 countries including the United States, Britain, Russia, Japan, Thailand, Malaysia, and Cambodia, via establishing strategic cooperation and localized examination with New Hope, MFC, Genetix, Foundation Lab, CRHG and other well-known reproductive medicine centers. Dedicated to provide personalized reproductive genetics solutions together with global colleagues in the reproduction field for infertility patients, our efficient and convenient precise prenatal and preimplantation genetic testing technologies such as NICS non-invasive embryo screening, 9-hour rapid embryo chromosome detection, etc. are promoted to the world through technical output.

In the future, Yikon Genomics will continue to take "mastering extraordinary technology to achieve billions health" as mission, and provide high-quality medical testing services for the health of countless people and new births to contribute to the development of precision medicine.

Suzhou (Operation, Inspection, Production)

01

Shanghai (Inspection, Business)

02

Beijing (Technical consulting, Business)

03

Guangzhou (Commercial Office)

04

Wuhan (Commercial Office)

05

Development Process

  • 01

    In June, Yikon Genomics was established in China Medical City, Taizhou, Jiangsu.

  • 02

    In October, Yikon Genomics Beijing Office was established.

  • 03

    In December, a high coverage single sperm genome atlas is realized by MALBAC, published on Science.

  • 01

    In June, an independent PGS laboratory was formally established jointly by Yikon Genomics and NEW HOPE.

  • 03

    Completed first high-precision human single egg cell sequencing in November, Cell.

  • 02

    In September, MALBAC technology is first applied to non-invasive cancer diagnosis, PNAS.

  • 01

    In September, the world's first healthy baby through blocking hereditary multiple osteochondroma by MALBAC-PGD technology was born (Beijing Third Hospital).

  • 02

    In November, the first healthy baby who blocked hypohidrosis-type ectodermal dysplasia was born (Beijing Third Hospital).

  • 01

    In April, Yikon Genomics received a Series-A funding of 60 million yuan. Xukang Medical Science & Technology (Suzhou) Co., Ltd was established in Suzhou Industrial Park and the registered capital is of 50 million yuan.

  • 02

    In November, Shanghai Yikon Medical Laboratory was established. The company's headquarters is located in Shanghai Business Park.

     

  • 03

    In December, the first hereditary healthy baby with blocked spinal muscle contraction was born (Beijing Third Hospital).

  • 04

    In December, the first healthy baby with blocked hereditary deafness was born (301 Hospital of PLA).

  • 01

    In January, Yikon Genomics's new visual recognition system was launched.

  • 02

    In March, the world's first healthy baby with noninvasive embryo chromosome screening (NICST) was born (Wuxi Women and Children) PNAS (September)

  • 03

    In August, the first healthy baby with blocked hereditary dominant polycystic kidney disease was born (Shanghai Changzheng Hospital).

  • 04

    In October, Yikon Genomics raised 150 million yuan in Series B round

  • 05

    In November, Taizhou Yikon Medical Laboratory was established.

  • 01

    In January, the world's first healthy baby with accurately blocked chromosomal balance translocation by MaReCS  was born.

  • 02

    In May, Yikon (Suzhou) production center officially started operation, covering an area of about 2,200 square meters, and the Class 1000,000 and Class 100,000 clean room reached 1,200 square meters.

  • 01

    In April, CEO Dr. Sijia Lu was elected as the deputy of the 15th Shanghai Municipal People's Congress.

  • 02

    In April, Yikon Genomics and Beijing 301 Hospital's cooperation project "Development and standardization of new technology for preimplantation genetic diagnosis" received special support from the national key research and development program "Reproductive health and the prevention and control of major birth defects".

     

  • 03

    In May, Yikon Genomics was approved to establish an academician expert workstation.

  • 04

    In July, CEO Dr. Sijia Lu was successfully selected into the "Innovative Talent Promotion Plan" of the national Ministry of Science and Technology.

     

  • 05

    In September, Taizhou Yikon Medical Laboratory Co., Ltd. was classified as the Jiangsu Single-cell Sequencing Genetic Testing Engineering Research Center.

     

  • 06

    In October, Xukang Medical Technology (Suzhou) Co., Ltd. was classified as high-tech enterprise in Jiangsu Province.

     

  • 01

    In January, Yikon Genomics participated in the establishment of the hereditary colorectal cancer screening and prevention and hereditary tumor family block center of Changhai Hospital.

  • 02

    In February, Xukang Medical successfully obtains both the ISO9001 and IS013485 quality management system certification.

  • 03

    In June, Yikon Genomics and NEW HOPE jointly established and officially operated an independent PGS laboratory.

     

  • 04

    In November, Yikon Genomics received the co-investment of RMB 220 million in Series C round from KINGHALL VENTURES (KingMed DiagnosisRelated Fund), Yuexiu Industrial Fund, Zhongyuan Jiupai Fund and Science and Technology Equity Investment Fund of Bank of Communications.

     

  • 01

    Online genetic consultation for rare diseases was launched in February.

  • 02

    Joined the Anti-epidemic and Anti-drug Joint Action Alliance in February.

  • 03

    The ESNi-PGT multi-center clinical trial is officially launched in April.

  • 04

    Full score in June passed the first inter-laboratory quality assessment of Shanghai Clinical Laboratory Center in 2020.

  • 05

    Listed in the "2020 Hurun China Cheetah Enterprise" in June.

  • 06

    August, passed the 2020 National Tumor Cell-free DNA Gene Mutation High-throughput Sequencing Laboratory Quality Assessment with full score.

  • 07

    August, passed the NCCL 2020 National Tumor Somatic Mutation High-throughput Sequencing Detection Bioinformatics Analysis Laboratory Quality Assessment with full score.

  • 08

    October, passed the NCCL 2020 National Solid Tumor Somatic Mutation High-throughput Sequencing Test Laboratory Quality Assessment with full score.

  • 09

    November, selected into "Top 50 Unicorns of New Medical Industry".

  • 10

    November, passed the NCCL 2020 National Chromosome Genome Structural Abnormality Laboratory Quality Assessment.

  • 11

    December, selected into the 2020 China Top 500 Invisible Unicorns.

  • 01

    In January, YiKon Genomics launched the whole genome big data screening and reproductive blocking project of Genetic Digestive tract tumors in Chinese population (Peking University Cancer Hospital).

  • 02

    In March, YiKon Genomics participated in YK-ERT national multi-center clinical trial.

  • 03

    In April,YiKon Genomics was listed in the Top 100 Future Medical Care 2020-2021.

  • 04

    In May,YiKon Genomics completed D round of RMB 250 million financing.

  • 05

    In May,YiKon Genomics Won the 2020 China Medical Science and Technology Award.

  • 06

    In June, YiKon Genomics established Shanghai Caohejing Business Center.

  • 07

    In June, YiKon Genomics passed the 2021 tumor cell-free DNA gene mutation high-throughput sequencing test laboratory quality evaluation with full score.

  • 08

    In June, YiKon Genomics "ChromSwift Single Cell Whole Genome Amplification Technology" Obtained U.S. Patent Authorization.

  • 09

    In June, YiKon Genomics established a strategic cooperation with Heyin Education & Yishan Genetics.

  • 10

    In July, YiKon Genomics passed the 2021 tumor cell-free DNA gene mutation high-throughput sequencing test laboratory quality evaluation with full score.

  • 11

    In August, YiKon Genomics was selected as "2021 Forbes China-Assisted Reproductive Industry Enterprise Top 10".

  • 12

    In August, YiKon Genomics established a strategic partnership with Ayers (ZheJiang) Medical Technology Co. LTD..

  • 13

    In August, YiKon Genomics established a strategic partnership with Genetron. 

  • 14

    In August, YiKon Genomics passed the 2021 National Tumor Somatic Mutation High-throughput Sequencing and Bioinformatics Analysis Laboratory Quality Assessment with full score.

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021

Core Team

Prof. Xiaoliang Sunney Xie

Founder & Chairman of Science Ad.

Dr. Sijia Lu

Chairman & Chief Executive Officer

Dr. Jun Ren

Chief Technology Officer

Dr. Yueming Jiang

Chief Operating Officer

Company Culture

Mission Vision

For the Health of Billions

Core Value

Focus on talents, customer-centric, innovation as the motivation
Persist in high efficiency, pragmatism, solidarity and excellent quality

Cooperative Partner

Global Market
Customer Oriented